Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03544281
Title To Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-drug Conjugate, GSK2857916 Administered in Combination With Lenalidomide Plus Dexamethasone (Arm A), or in Combination With Bortezomib Plus Dexamethasone (Arm B) in Subjects With Relapsed/Refractory Multiple Myeloma (RRMM)
Acronym DREAMM 6
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors GlaxoSmithKline
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | GBR | ESP | CAN | AUS

Facility Status City State Zip Country Details
GSK Investigational Site Birmingham Alabama 35294 United States Details
GSK Investigational Site Goodyear Arizona 85338 United States Details
GSK Investigational Site Atlanta Georgia 30322-4200 United States Details
GSK Investigational Site Indianapolis Indiana 46202 United States Details
GSK Investigational Site Lansing Michigan 48910 United States Details
GSK Investigational Site Saint Louis Missouri 63110 United States Details
GSK Investigational Site Grand Island Nebraska 68803 United States Details
GSK Investigational Site Hackensack New Jersey 07601 United States Details
GSK Investigational Site Bronx New York 10467 United States Details
GSK Investigational Site New York New York 10022 United States Details
GSK Investigational Site Greer South Carolina 29650 United States Details
GSK Investigational Site Dallas Texas 75251 United States Details
GSK Investigational Site Wollongong New South Wales 2500 Australia Details
GSK Investigational Site Woodville South Australia 5011 Australia Details
GSK Investigational Site Fitzroy Victoria 3065 Australia Details
GSK Investigational Site Melbourne Victoria 3000 Australia Details
GSK Investigational Site Melbourne Victoria 3004 Australia Details
GSK Investigational Site Murdoch Western Australia 6150 Australia Details
GSK Investigational Site Nedlands Western Australia 6009 Australia Details
GSK Investigational Site Montreal Quebec H1T 2M4 Canada Details
GSK Investigational Site Barcelona 8035 Spain Details
GSK Investigational Site Madrid 28040 Spain Details
GSK Investigational Site Madrid 28050 Spain Details
GSK Investigational Site Salamanca 37007 Spain Details
GSK Investigational Site Truro Cornwall TR1 3LJ United Kingdom Details
GSK Investigational Site London W1T 7HA United Kingdom Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field